RhoVac appoints new Chief Development Officer
Rhovac’s drug candidate, RV001, is being developed with the goal of targeting and destroying cancer cells with the potential to metastasise and a crucial phase IIb study is currently underway. With RhoVac’s Chief Operating Officer (COO), Anders Ljungqvist, approaching retirement, some managerial re-organisation is taking place at the company, and, in January, Steffen Wad Jørgensen has […].